Related Experiment Video
Updated: Mar 14, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP
P J Paul1,2, D Raghu1,2, A-L Chan2
1The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Abstract:
Restoration of tumor suppression is an attractive onco-therapeutic approach. It is particularly relevant when a tumor suppressor is excessively degraded by an overactive oncogenic E3 ligase. We previously discovered that the E6-associated protein (E6AP; as classified in the human papilloma virus context) is an E3 ligase that has an important role in the cellular stress response, and it directly targets the tumor-suppressor promyelocytic leukemia protein (PML) for proteasomal degradation. In this study, we have examined the role of the E6AP-PML axis in prostate cancer (PC). We show that knockdown (KD) of E6AP expression attenuates growth of PC cell lines in vitro. We validated this finding in vivo using cell line xenografts, patient-derived xenografts and mouse genetics. We found that KD of E6AP attenuates cancer cell growth by promoting cellular senescence in vivo, which correlates with restoration of tumor suppression by PML. In addition, we show that KD of E6AP sensitizes cells to radiation-induced death. Overall, our findings demonstrate a role for E6AP in the promotion of PC and support E6AP targeting as a novel approach for PC treatment, either alone or in combination with radiation.
Insights
Targeting E3 ligase E6-associated protein (E6AP) inhibits prostate cancer (PC) growth by restoring tumor suppressor PML. Knockdown of E6AP promotes senescence and sensitizes tumors to radiation therapy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Restoring tumor suppressor function is a key cancer therapy strategy.
- E3 ligase E6-associated protein (E6AP) targets the tumor suppressor promyelocytic leukemia protein (PML) for degradation.
- The E6AP-PML interaction's role in prostate cancer (PC) is not fully understood.
Purpose of the Study:
- To investigate the role of the E6AP-PML axis in prostate cancer progression.
- To evaluate E6AP as a potential therapeutic target for PC.
Main Methods:
- Knockdown (KD) of E6AP in PC cell lines and in vivo models (xenografts, patient-derived xenografts, mouse genetics).
- Assessed PC cell growth, cellular senescence, and response to radiation.
- Examined the impact on PML levels and tumor suppressor activity.
Main Results:
- E6AP knockdown significantly attenuated PC cell growth in vitro and in vivo.
- E6AP KD promoted cellular senescence and restored tumor suppressor function of PML.
- E6AP knockdown sensitized PC cells to radiation-induced death.
Conclusions:
- E6AP promotes prostate cancer progression.
- Targeting E6AP is a promising therapeutic strategy for PC, potentially in combination with radiation therapy.
Related Concept Videos
Abnormal Proliferation
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

